中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
5期
652-654
,共3页
王健%曹东%顾文静%陈清华%殷建平%平小英%胡平%杨潋
王健%曹東%顧文靜%陳清華%慇建平%平小英%鬍平%楊瀲
왕건%조동%고문정%진청화%은건평%평소영%호평%양렴
恶性肿瘤%WHO标准%RECIST标准%疗效
噁性腫瘤%WHO標準%RECIST標準%療效
악성종류%WHO표준%RECIST표준%료효
Malignant tumor%WHO criteria%RECIST%Treatment response
目的 评价WHO标准与RECIST标准对恶性肿瘤治疗0疗效评价的一致性.方法 分别采用WHO标准和RECIST标准对137例接受治疗或随访的恶性肿瘤患者的疗效进行评估.测量肿瘤最长径和最大垂直径,分别以最长径与最大垂直径乘积之和、最长径之和评价疗效.疗效分为完全缓解、部分缓解、疾病稳定、疾病进展.使用x2检验比较两种疗效评价标准的结果.结果 共测量268个病灶.两种标准在120例(87.6%)患者中的疗效评价一致,采用RECIST标准在13例患者中评价较WHO标准提高,另外4例患者的评价降低.两种标准评价治疗的总有效率和疾病进展率差异均无统计学意义.结论 RECIST标准与WHO标准具有较好的一致性.RECIST标准较WHO标准简单易用,可用于恶性肿瘤治疗疗效的评价.
目的 評價WHO標準與RECIST標準對噁性腫瘤治療0療效評價的一緻性.方法 分彆採用WHO標準和RECIST標準對137例接受治療或隨訪的噁性腫瘤患者的療效進行評估.測量腫瘤最長徑和最大垂直徑,分彆以最長徑與最大垂直徑乘積之和、最長徑之和評價療效.療效分為完全緩解、部分緩解、疾病穩定、疾病進展.使用x2檢驗比較兩種療效評價標準的結果.結果 共測量268箇病竈.兩種標準在120例(87.6%)患者中的療效評價一緻,採用RECIST標準在13例患者中評價較WHO標準提高,另外4例患者的評價降低.兩種標準評價治療的總有效率和疾病進展率差異均無統計學意義.結論 RECIST標準與WHO標準具有較好的一緻性.RECIST標準較WHO標準簡單易用,可用于噁性腫瘤治療療效的評價.
목적 평개WHO표준여RECIST표준대악성종류치료0료효평개적일치성.방법 분별채용WHO표준화RECIST표준대137례접수치료혹수방적악성종류환자적료효진행평고.측량종류최장경화최대수직경,분별이최장경여최대수직경승적지화、최장경지화평개료효.료효분위완전완해、부분완해、질병은정、질병진전.사용x2검험비교량충료효평개표준적결과.결과 공측량268개병조.량충표준재120례(87.6%)환자중적료효평개일치,채용RECIST표준재13례환자중평개교WHO표준제고,령외4례환자적평개강저.량충표준평개치료적총유효솔화질병진전솔차이균무통계학의의.결론 RECIST표준여WHO표준구유교호적일치성.RECIST표준교WHO표준간단역용,가용우악성종류치료료효적평개.
Objective To evaluate the agreement of treatment response between WHO and RECIST criteria for malignant tumor.Methods The treatment response rate of 137 patients with malignant tumor was evaluated by WHO and RECIST criteria respectively.The largest diameter and perpendicular diameter of tumor were measured.The curative effect was calculated by the product of multiplication of the largest perpendicular diameters and the sum of the largest diameters respectively.The response evaluation was categorized into CR,PR,SD and PD according to WHO and RECIST criteria.Differences in response assessment between the two techniques were compared statistically according to the x2 test.Results A total of 268 lesions were analyzed.The two techniques were concordant in 120 classifications(87.6%).The response assessment produced by RECIST was improved compared with that of WHO criteria in 13 patients,and worse in 4 patients,respectively.There was no significant difference between the total effective rate and the progressive rate judged by the two criteria.Conclusion There is a good agreement between WHO and RECIST criteria.RECIST is simpler and easier than WHO criteria,and it is appropriate for assessing the treatment response in malignant tumor